What Does Elevated Troponin Mean in COVID-19?

Allan Jaffe

Ambulatory Blood Pressure Monitoring

William White

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Cardiac CT in 2023: From Anatomy to Physiology to Plaque Burden and …

Michael Gallagher

AHA 2022: Chlorthalidone Compared to Hydrochlorothiazide for the Pre…

AHA 2022 Conference Coverage

A. Ishani

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

New Insights into Triglyceride Therapy and the Role of Omega-3 Fatty…

National Lipid Association

R. Mason

Should Colchicine Become Standard Therapy for CAD?

Canadian Collaborative Research Network

P. Ridker

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

ACC 2022: Triple Therapy - When to Use and How Long

ACC 2022 Conference Coverage

D. Kumbhani

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Weightloss in Menopause

Susan Brian

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Directions of Cardiology in the Next Decade: 2022-2032

Houston Methodist DeBakey Heart and Vascular Center

E. Braunwald

Tirzepatide Updates

Diana Isaacs